Skip to main content
European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Psychiatric Ratings using Intermediate Stratified Markers 2

Projektbeschreibung

Neue Biomarker zur Klassifizierung neuropsychiatrischer Erkrankungen

Für die Klassifizierung neuropsychiatrischer Erkrankungen wie Schizophrenie, deren biologische Ursachen noch unklar sind, werden vor allem bildgebende Biomarker und klinische Endpunkte benötigt. Quantitative Biomarker könnten neben der Klassifizierung auch die Arzneimittelentwicklung beschleunigen. Das EU-finanzierte Projekt PRISM 2 baut auf Erkenntnissen des Vorgängerprojekts PRISM 1 zu diagnostischen Biomarkern und sozialen Aspekten bei Schizophrenie und Alzheimer-Demenz auf und soll diese auf Depressionserkrankungen erweitern. Ziel sind verlässliche Biomarker für die Diagnose und personalisierte Therapie neuropsychiatrischer Erkrankungen.

Ziel

The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.

Koordinator

RIJKSUNIVERSITEIT GRONINGEN
Netto-EU-Beitrag
€ 1 024 422,50
Adresse
Broerstraat 5
9712CP Groningen
Niederlande

Auf der Karte ansehen

Region
Noord-Nederland Groningen Overig Groningen
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 1 624 422,50

Beteiligte (17)